Early, accurate detection is key
75% of PAD patients are asymptomatic and are not aware of their risk. Current Ankle-Brachial Index (ABI) testing methods are difficult to administer, often inaccurate and can be uncomfortable for patients. These challenges can lead to false negative test results, putting patients at unncessary risk of limb loss or premature mortaility.
Fast, accurate, easy diagnosis
UltraSense is a disruptive ultrasound technology combined with an AI platform that provides clinicians with the insight needed for appropriate treatment and prevention. UltraSense’s ease of use, reliability and accuracy reduce medical staff training, lower the cost of diagnosis and improve patient comfort. Primary care givers can now confidently diagnose PAD, enabling early diagnosis and treatment. With early detection and treatment, limbs and lives can be saved.
Multi-element probe
- Quick, accurate vessel location
- No more doppler pencil probe frustration
- Hands-free vessel location, regardless of body type
- Enhanced patient comfort
- Adheres to CMS reimbursement guidelines
Stochastic resonance technology
- Boosts weak signals
- Allows clinician to hear what legacy systems cannot
- Eliminates test variability
- Decreases test time by over 70%
Advanced AI analysis
- Quick and accurate diagnosis
- Easy-to-understand reports
- Minimal staff training required
- Identification of key PAD indicators
Subscribe to our newsletter “CorRen Chronicles” for the latest news
Our Partners
